Targeting TDP-43 Pathology Alleviates Cognitive and Motor Deficits Caused by Chronic Cerebral Hypoperfusion

Sai Sampath Thammisetty1,2, Laurence Renaud1, Vincent Picher-Martel1,3

  • 1CERVO Brain Research Centre, Quebec City, Canada.

Insights

Chronic brain hypoperfusion causes TDP-43 pathology and cognitive deficits in mice. A novel drug (IMS-088) mitigated these effects, suggesting a potential treatment for vascular dementia.

Area of Science:

  • Neuroscience
  • Pathology
  • Pharmacology

Background:

  • Vascular dementia is a common neurodegenerative disease linked to cerebrovascular issues.
  • The precise molecular mechanisms and TDP-43 protein's role in vascular dementia are not fully understood.
  • TDP-43 mislocalization is a key pathological hallmark observed in neurodegenerative conditions.

Purpose of the Study:

  • To investigate the impact of chronic cerebral hypoperfusion (CCH) on TDP-43 pathology and cognitive function in a mouse model.
  • To evaluate the therapeutic potential of a novel withaferin A analog (IMS-088) in mitigating CCH-induced neuropathology and deficits.

Main Methods:

  • Induction of CCH in mice via unilateral common carotid artery occlusion.
  • Assessment of TDP-43 mislocalization, aggregation, microglial activation, and cognitive/motor functions.
  • Administration of IMS-088 and evaluation of its effects on TDP-43 pathology, autophagy, and behavioral deficits.

Main Results:

  • CCH induced cytoplasmic TDP-43 mislocalization and insoluble phospho-TDP-43 aggregates in mice, mirroring human vascular dementia pathology.
  • CCH led to chronic microglial activation, neuroinflammation, cognitive decline, and motor impairments.
  • IMS-088 treatment ameliorated TDP-43 pathology, enhanced autophagy, and improved cognitive and motor deficits in CCH mice.

Conclusions:

  • TDP-43 pathogenic inclusions are implicated in dementia resulting from chronic brain hypoperfusion.
  • Targeting TDP-43 pathology with agents like IMS-088 shows promise for treating vascular dementia.
  • The study highlights a potential disease-modifying strategy for hypoperfusion-induced dementia.